pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
239
stories
Oct 12, 26
Bristol Myers dips on ‘confounding’ lung drug results
biopharma dive
Oct 12, 26
Bausch + Lomb swaps CEOs; Merck reveals anticipated eye drug data
biopharma dive
Oct 8, 26
Argenx falls as Sjögren’s setback offsets celiac drug progress
biopharma dive
Oct 8, 26
Argenx shutters Sjogren's study, losing blockbuster expansion opportunity for Vyvgart
biospace
Oct 8, 26
Argenx digests phase 2 celiac win for $2.2B drug, preps pivotal run
fiercebiotech
Oct 7, 26
ArriVent sheds nearly half of value on late-stage lung cancer miss
biospace
Oct 2, 26
Novartis bets up to $7.8B for an mRNA-encoded T cell engager from China’s Abogen
biospace
Oct 2, 26
Novartis pens $7.8B deal for Abogen's in vivo autoimmune T-cell engager
fiercebiotech
Oct 1, 26
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
Oct 1, 26
Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken
fiercebiotech
Sep 30, 26
Bristol Myers trial revisions shake confidence in new class of fibrosis drugs
biopharma dive
Sep 30, 26
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody
fiercebiotech
Sep 28, 26
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
Sep 28, 26
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
Sep 25, 26
How NIH’s Nicole Kleinstreuer is working to reduce animal testing while avoiding a ‘backlash’
fiercebiotech
Sep 24, 26
Chutes & Ladders—Travere chief makes way for former Amicus CEO
fiercebiotech
Sep 24, 26
China’s Henlius carves out $440M T-cell engager deal with Amberstone
fiercebiotech
Sep 24, 26
The human cost of AI interviews
biospace
Sep 23, 26
Amgen asset from $27.8B Horizon buy scores in Phase 3 Sjögren's study
biospace
Sep 23, 26
9 companies hiring in Pennsylvania now
biospace
Sep 22, 26
Amgen reports a Phase 3 win with Sjögren’s drug candidate
biopharma dive
Sep 22, 26
Amgen's Phase 3 Sjögren's win; Novartis' $900M radioligand deal
endpoints
Sep 22, 26
GSK aiming to ‘balance West and East’ after Hansoh deal success showed China’s potential
fiercebiotech
Sep 22, 26
Amgen’s Horizon-acquired fusion protein eases Sjögren's severity in ph. 3 win
fiercebiotech
Sep 21, 26
Citing Replimune approval, experts say localized cancer meds could redefine care
biospace
Sep 17, 26
Trending: Top biopharma disciplines with jobs live now
biospace
Sep 17, 26
Biopharma hiring hotspots: States, disciplines where demand is highest
biospace
Sep 16, 26
Sling banks $123M for an experimental thyroid eye disease pill
biopharma dive
Sep 16, 26
Sling catches $123M series C for thyroid eye disease pill
biospace
Sep 15, 26
Sling reels in $123M series C to fund oral Tepezza rival through phase 3 trial
fiercebiotech
← prev
page 3 of 8
next →